Search results
Results From The WOW.Com Content Network
Type 1 and 2 diabetes was estimated to cause $10.5 billion in annual medical costs ($875 per month per diabetic) and an additional $4.4 billion in indirect costs ($366 per month per person with diabetes) in the U.S. [116] In the United States $245 billion every year is attributed to diabetes. Individuals diagnosed with diabetes have 2.3 times ...
Demonstration that intensive glycemic control in type 1 diabetes reduces chronic side effects more as glucose levels approach 'normal' in a large longitudinal study, [149] and also in type 2 diabetics in other large studies; Identification of the first thiazolidinedione as an effective insulin sensitizer during the 1990s
Ketosis-prone diabetes (KPD) is an intermediate form of diabetes that has some characteristics of type 1 and some of type 2 diabetes. Type 1 diabetes involves autoimmune destruction of pancreatic beta cells which create insulin.
The condition is strongly associated with or caused by type 2 diabetes, insulin resistance, and metabolic syndrome (defined as at least three of the five following medical conditions: abdominal obesity, high blood pressure, high blood sugar, high serum triglycerides, and low serum high-density lipoprotein).
It is the most common [1]: 540 [2]: 681 of several diabetic skin conditions, being found in up to 30% of diabetics. Similar lesions can occasionally be found in non-diabetics usually following trauma or injury to the area; however, more than 4 lesions strongly suggests diabetes.
The mean age of onset since diagnosis of diabetes is fifteen years. The female:male ratio is 1.3:1. The female:male ratio is 1.3:1. Other diabetic complications such as nephropathy , neuropathy , retinopathy and hypertension are usually present.
It was initially thought to be a form of maturity onset diabetes of the young, [32] and went through several other descriptive names (such as "idiopathic type 1 diabetes", "Flatbush diabetes", "atypical diabetes" and "type 1.5 diabetes") before the current terminology of "ketosis-prone type 2 diabetes" was adopted. [3] [22]
In the DCCT (Diabetes Control and Complications Trial, 1995) study, the annual incidence of neuropathy was 2% per year but dropped to 0.56% with intensive treatment of Type 1 diabetics. The progression of neuropathy is dependent on the degree of glycemic control in both Type 1 and Type 2 diabetes.